Literature DB >> 23846923

First line therapy for metastatic pancreatic cancer.

Jamie Jarboe1, Muhammad Wasif Saif.   

Abstract

Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week. We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23846923     DOI： 10.6092/1590-8577/1667

Source DB:  PubMed          Journal:  JOP        ISSN： 1590-8577


  3 in total

1.  First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

Authors:  Muhammad Wasif Saif; Jia Li; Lynne Lamb; Kristin Kaley; Kyle Elligers; Zaoli Jiang; Scott Bussom; Shwu-Huey Liu; Yung-Chi Cheng
Journal:  Cancer Chemother Pharmacol       Date:  2013-12-03       Impact factor: 3.333

Review 2.  Intervention on toll-like receptors in pancreatic cancer.

Authors:  Juan Vaz; Roland Andersson
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 3.  Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.

Authors:  Daniel Neureiter; Tarkan Jäger; Matthias Ocker; Tobias Kiesslich
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.